Dr Reddys Laboratories (RDY) Long-Term Deferred Tax (2017 - 2026)
Dr Reddys Laboratories has reported Long-Term Deferred Tax over the past 10 years, most recently at $245.4 million for Q1 2026.
- For Q1 2026, Long-Term Deferred Tax rose 14.83% year-over-year to $245.4 million; the TTM value through Mar 2026 reached $245.4 million, up 14.83%, while the annual FY2026 figure was $245.4 million, 13.1% up from the prior year.
- Long-Term Deferred Tax for Q1 2026 was $245.4 million at Dr Reddys Laboratories, up from $213.7 million in the prior quarter.
- Over five years, Long-Term Deferred Tax peaked at $245.4 million in Q1 2026 and troughed at $87.5 million in Q1 2023.
- A 5-year average of $157.1 million and a median of $129.7 million in 2024 define the central range for Long-Term Deferred Tax.
- Biggest five-year swings in Long-Term Deferred Tax: decreased 25.16% in 2022 and later soared 64.74% in 2025.
- Year by year, Long-Term Deferred Tax stood at $109.1 million in 2022, then decreased by 19.77% to $87.5 million in 2023, then soared by 48.2% to $129.7 million in 2024, then soared by 64.74% to $213.7 million in 2025, then grew by 14.83% to $245.4 million in 2026.
- Business Quant data shows Long-Term Deferred Tax for RDY at $245.4 million in Q1 2026, $213.7 million in Q1 2025, and $129.7 million in Q1 2024.